Ballabh P, Braun A, Nedergaard M Anatomic analysis of blood vessels in germinal matrix, cerebral cortex, and white matter in developing infants. Pediatr Res. 2004 Jul;56(1):117-24. Epub 2004 May 5.
Benninger KL, Maitre NL, Ruess L, Rusin JA MR Imaging Scoring System for White Matter Injury after Deep Medullary Vein Thrombosis and Infarction in Neonates. AJNR Am J Neuroradiol. 2019 Feb;40(2):347-352. doi: 10.3174/ajnr.A5940. Epub 2019 Jan 17.
du Plessis AJ Cerebrovascular injury in premature infants: current understanding and challenges for future prevention. Clin Perinatol. 2008 Dec;35(4):609-41, v. doi: 10.1016/j.clp.2008.07.010. Review.
Gould SJ, Howard S, Hope PL, Reynolds EO Periventricular intraparenchymal cerebral haemorrhage in preterm infants: the role of venous infarction. J Pathol. 1987 Mar;151(3):197-202.
Guihard-Costa AM, Larroche JC Differential growth between the fetal brain and its infratentorial part. Early Hum Dev. 1990 Jun;23(1):27-40.
Nakamura Y, Okudera T, Hashimoto T Vascular architecture in white matter of neonates: its relationship to periventricular leukomalacia. J Neuropathol Exp Neurol. 1994 Nov;53(6):582-9.
Vilan A, Ribeiro JM, Reis C, Sampaio L Deep Medullary Veins and Brain Injury. J Pediatr. 2018 Sep;200:290-290.e1. doi: 10.1016/j.jpeds.2018.03.051. Epub 2018 May 3.
Yang JY, Chan AK, Callen DJ, Paes BA Neonatal cerebral sinovenous thrombosis: sifting the evidence for a diagnostic plan and treatment strategy. Pediatrics. 2010 Sep;126(3):e693-700. doi: 10.1542/peds.2010-1035. Epub 2010 Aug 9. Review.
A Cohort Study on the Etiology and Pathological Types of Brain White Matter Injury in Late Preterm Infants
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
